<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650324</url>
  </required_header>
  <id_info>
    <org_study_id>DBPR108-101</org_study_id>
    <nct_id>NCT01650324</nct_id>
  </id_info>
  <brief_title>A Single-dose Phase 1 Study of DBPR108 in Healthy Male Subjects</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Dose-ranging, Single-dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DBPR108 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being performed to assess the safety, tolerability, and pharmacokinetic (PK) and
      pharmacodynamic (PD) properties of single oral doses of DBPR108 in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study represents the first administration of dipeptidyl peptidase 4 (DPP4) inhibitor
      DBPR108 to humans to evaluate the safety, tolerability, and pharmacokinetic (PK) and
      pharmacodynamic (PD) properties following single oral doses in healthy subjects.

      DPP4 is a validated drug target for the treatment of human type 2 diabetes. Objectives of the
      study will be to characterize the safety and tolerability of single doses of DBPR108; to
      characterize the single dose PK of DBPR108 in plasma and urine; to characterize the single
      dose PD of DBPR108 on glucose, glucagon, dipeptidyl peptidase 4 activity, and total and
      active forms of glucagon-like peptide-1 (GLP-1) in plasma levels and insulin and C-peptide in
      serum levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Adverse events were collected from Day -1 (baseline) through the end of the study, up to Day 7.</time_frame>
    <description>There were 4 mild adverse events observed during the course of study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics - Area Under the Plasma Concentration-Time Curve (AUC From 0 to Infinity)</measure>
    <time_frame>predose (0 hr), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hrs post dose</time_frame>
    <description>Plasma samples were used to determine the AUC from time 0 to infinity for DBPR108. The placebo group is not included in the table below; this outcome measure only evaluated the DBPR108 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics - Observed Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>predose (0 hr), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hrs post dose</time_frame>
    <description>Plasma samples were used to determine the Cmax for DBPR108. The placebo group is not included in the table below; this outcome measure only evaluated the DBPR108 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics - Time of Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>predose (0 hr), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hrs post dose</time_frame>
    <description>Plasma samples were used to determine the Time of Maximum Plasma Concentration for DBPR108. The placebo group is not included in the table below; this outcome measure only evaluated the DBPR108 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Dipeptidyl Peptidase 4 (DPP4) Activities Between 48 Hrs Post Dose and 0 hr Predose</measure>
    <time_frame>predose (0 hr) and 48 hrs post dose</time_frame>
    <description>Change of plasma DPP4 activity at 48 hrs post dose from predose (0 hr). The values were computed as areas under the DPP4 activity-time curve using ANCOVA model, in which the unit of the activity is pmol/min.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>DBPR108</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DBPR108</intervention_name>
    <description>DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.</description>
    <arm_group_label>DBPR108</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.</description>
    <arm_group_label>matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male with suitable veins for cannulation or repeated venipuncture, and must be able to
             swallow the study drug intact;

          -  Aged between 20 and 45 years (inclusive) at the screening visit; and

          -  Able to provide written informed consent and willing to comply with the study protocol
             procedures and restrictions.

        Exclusion Criteria:

          -  Has a body weight less than 50 kg and/or body mass index (BMI) less than 18 kg/m2 or
             greater than 30 kg/m2 at the screening visit;

          -  Has a creatinine clearance (Ccr) less than 80 mL/min at screening;

          -  Is not in good general health as judged by the Investigator based on routine medical
             history, vital signs, physical examination, ECG, laboratory tests, and urinalysis at
             the screening visit or at admission for the residential period;

          -  Is not normoglycemic defined as fasting glucose at less than 70 mg/dL (3.9 mmol/L) and
             greater than 100 mg/dL (5.5 mmol/L);

          -  Has a platelet count less than 150,000/ÂµL;

          -  Uses any antihyperglycemic agents at screening or at admission for the residential
             period;

          -  Has a history or presence of any disease or condition known to interfere with the
             absorption, distribution, metabolism, or excretion of drugs at the screening visit or
             at admission for the residential period;

          -  Has a clinically significant psychiatric, renal, hepatic, cardiovascular,
             gastrointestinal, or neurologic disease at screening or at admission for the
             residential period;

          -  Is a smoker and/or has used nicotine-containing products within the last 6 months
             prior to the screening for the current study and/or has a history of alcohol abuse;

          -  Has donated blood or participated in another clinical study within 8 weeks preceding
             the day of admission;

          -  Excessive intake of caffeine-containing drinks or food (ie, coffee, tea, chocolate,
             PAOLYTA B Liq, WHISBIH Liq, or cola [more than 6 units of caffeine per day]);

          -  Use of drugs with enzyme-inducing properties such as St. John's Wort within 4 weeks
             prior to the first administration of investigational product;

          -  Has used prescription or nonprescription medication (except for occasional use of
             paracetamol or nasal spray) or herbal remedies or vitamins or minerals within 2 weeks
             or 5 half-lives of the drug, whichever is longer, prior to dosing until end of study;

          -  Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade,
             or other products containing grapefruit or Seville oranges within 7 days of the first
             administration of investigational product;

          -  Male subjects who are unwilling to use barrier contraception in addition to having
             their partner use another method of contraception, for the duration of the study and
             for 3 months after dosing;

          -  Has a positive result on screening for serum hepatitis B surface antigen (HBsAg),
             hepatitis C antibody (HCVAb), or human immunodeficiency virus (HIV);

          -  Has received a blood transfusion and/or has HCV infection;

          -  Positive result on screening for drugs of abuse, alcohol, or cotinine (nicotine) at
             screening or admission; or

          -  Involved in the planning or conduct of the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Taipei Medical University - Wanfang Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>116</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2012</study_first_submitted>
  <study_first_submitted_qc>July 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <results_first_submitted>May 20, 2014</results_first_submitted>
  <results_first_submitted_qc>August 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 28, 2014</results_first_posted>
  <last_update_submitted>August 15, 2014</last_update_submitted>
  <last_update_submitted_qc>August 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DBPR108</keyword>
  <keyword>DPP4</keyword>
  <keyword>Diabetes</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Incretins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received either a single oral dose of matching placebo to DBPR108 25 mg, 100 mg, 300 mg, or 600 mg</description>
        </group>
        <group group_id="P2">
          <title>DBPR108 25 mg</title>
          <description>Participants received a single oral dose of DBPR108 25 mg</description>
        </group>
        <group group_id="P3">
          <title>DBPR108 100 mg</title>
          <description>Participants received a single oral dose of DBPR108 100 mg</description>
        </group>
        <group group_id="P4">
          <title>DBPR108 300 mg</title>
          <description>Participants received a single oral dose of DBPR108 300 mg</description>
        </group>
        <group group_id="P5">
          <title>DBPR108 600 mg</title>
          <description>Participants received a single oral dose of DBPR108 600 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received either a single oral dose of matching placebo to DBPR108 25 mg, 100 mg, 300 mg, or 600 mg</description>
        </group>
        <group group_id="B2">
          <title>DBPR108 25 mg</title>
          <description>Participants received a single oral dose of DBPR108 25 mg</description>
        </group>
        <group group_id="B3">
          <title>DBPR108 100 mg</title>
          <description>Participants received a single oral dose of DBPR108 100 mg</description>
        </group>
        <group group_id="B4">
          <title>DBPR108 300 mg</title>
          <description>Participants received a single oral dose of DBPR108 300 mg</description>
        </group>
        <group group_id="B5">
          <title>DBPR108 600 mg</title>
          <description>Participants received a single oral dose of DBPR108 600 mg</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="8"/>
                    <measurement group_id="B2" value="26" spread="2"/>
                    <measurement group_id="B3" value="24" spread="2"/>
                    <measurement group_id="B4" value="27" spread="5"/>
                    <measurement group_id="B5" value="26" spread="6"/>
                    <measurement group_id="B6" value="27" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
        <description>There were 4 mild adverse events observed during the course of study.</description>
        <time_frame>Adverse events were collected from Day -1 (baseline) through the end of the study, up to Day 7.</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received either a single oral dose of matching placebo to DBPR108 25 mg, 100 mg, 300 mg, or 600 mg</description>
          </group>
          <group group_id="O2">
            <title>DBPR108 25 mg</title>
            <description>Participants received a single oral dose of DBPR108 25 mg</description>
          </group>
          <group group_id="O3">
            <title>DBPR108 100 mg</title>
            <description>Participants received a single oral dose of DBPR108 100 mg</description>
          </group>
          <group group_id="O4">
            <title>DBPR108 300 mg</title>
            <description>Participants received a single oral dose of DBPR108 300 mg</description>
          </group>
          <group group_id="O5">
            <title>DBPR108 600 mg</title>
            <description>Participants received a single oral dose of DBPR108 600 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
          <description>There were 4 mild adverse events observed during the course of study.</description>
          <population>All enrolled participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Profile of Pharmacokinetics - Area Under the Plasma Concentration-Time Curve (AUC From 0 to Infinity)</title>
        <description>Plasma samples were used to determine the AUC from time 0 to infinity for DBPR108. The placebo group is not included in the table below; this outcome measure only evaluated the DBPR108 groups.</description>
        <time_frame>predose (0 hr), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hrs post dose</time_frame>
        <population>All participants who received a single dose of DBPR108 25 mg, 100 mg, 300 mg, or 600 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>DBPR108 25 mg</title>
            <description>Participants received a single oral dose of DBPR108 25 mg</description>
          </group>
          <group group_id="O2">
            <title>DBPR108 100 mg</title>
            <description>Participants received a single oral dose of DBPR108 100 mg</description>
          </group>
          <group group_id="O3">
            <title>DBPR108 300 mg</title>
            <description>Participants received a single oral dose of DBPR108 300 mg</description>
          </group>
          <group group_id="O4">
            <title>DBPR108 600 mg</title>
            <description>Participants received a single oral dose of DBPR108 600 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Profile of Pharmacokinetics - Area Under the Plasma Concentration-Time Curve (AUC From 0 to Infinity)</title>
          <description>Plasma samples were used to determine the AUC from time 0 to infinity for DBPR108. The placebo group is not included in the table below; this outcome measure only evaluated the DBPR108 groups.</description>
          <population>All participants who received a single dose of DBPR108 25 mg, 100 mg, 300 mg, or 600 mg.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236" spread="66.9"/>
                    <measurement group_id="O2" value="1310" spread="290"/>
                    <measurement group_id="O3" value="3910" spread="1200"/>
                    <measurement group_id="O4" value="10500" spread="2400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Profile of Pharmacokinetics - Observed Maximum Plasma Concentration (Cmax)</title>
        <description>Plasma samples were used to determine the Cmax for DBPR108. The placebo group is not included in the table below; this outcome measure only evaluated the DBPR108 groups.</description>
        <time_frame>predose (0 hr), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hrs post dose</time_frame>
        <population>All participants who received a single dose of DBPR108 25 mg, 100 mg, 300 mg, or 600 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>DBPR108 25 mg</title>
            <description>Participants received a single oral dose of DBPR108 25 mg</description>
          </group>
          <group group_id="O2">
            <title>DBPR108 100 mg</title>
            <description>Participants received a single oral dose of DBPR108 100 mg</description>
          </group>
          <group group_id="O3">
            <title>DBPR108 300 mg</title>
            <description>Participants received a single oral dose of DBPR108 300 mg</description>
          </group>
          <group group_id="O4">
            <title>DBPR108 600 mg</title>
            <description>Participants received a single oral dose of DBPR108 600 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Profile of Pharmacokinetics - Observed Maximum Plasma Concentration (Cmax)</title>
          <description>Plasma samples were used to determine the Cmax for DBPR108. The placebo group is not included in the table below; this outcome measure only evaluated the DBPR108 groups.</description>
          <population>All participants who received a single dose of DBPR108 25 mg, 100 mg, 300 mg, or 600 mg.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2" spread="23.8"/>
                    <measurement group_id="O2" value="187" spread="33.3"/>
                    <measurement group_id="O3" value="571" spread="158"/>
                    <measurement group_id="O4" value="1370" spread="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Profile of Pharmacokinetics - Time of Maximum Plasma Concentration (Tmax)</title>
        <description>Plasma samples were used to determine the Time of Maximum Plasma Concentration for DBPR108. The placebo group is not included in the table below; this outcome measure only evaluated the DBPR108 groups.</description>
        <time_frame>predose (0 hr), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hrs post dose</time_frame>
        <population>All participants who received a single dose of DBPR108 25 mg, 100 mg, 300 mg, or 600 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>DBPR108 25 mg</title>
            <description>Participants received a single oral dose of DBPR108 25 mg</description>
          </group>
          <group group_id="O2">
            <title>DBPR108 100 mg</title>
            <description>Participants received a single oral dose of DBPR108 100 mg</description>
          </group>
          <group group_id="O3">
            <title>DBPR108 300 mg</title>
            <description>Participants received a single oral dose of DBPR108 300 mg</description>
          </group>
          <group group_id="O4">
            <title>DBPR108 600 mg</title>
            <description>Participants received a single oral dose of DBPR108 600 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Profile of Pharmacokinetics - Time of Maximum Plasma Concentration (Tmax)</title>
          <description>Plasma samples were used to determine the Time of Maximum Plasma Concentration for DBPR108. The placebo group is not included in the table below; this outcome measure only evaluated the DBPR108 groups.</description>
          <population>All participants who received a single dose of DBPR108 25 mg, 100 mg, 300 mg, or 600 mg.</population>
          <units>hrs</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="4.02" lower_limit="1.50" upper_limit="4.03"/>
                    <measurement group_id="O3" value="4.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="4.01" lower_limit="2.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Dipeptidyl Peptidase 4 (DPP4) Activities Between 48 Hrs Post Dose and 0 hr Predose</title>
        <description>Change of plasma DPP4 activity at 48 hrs post dose from predose (0 hr). The values were computed as areas under the DPP4 activity-time curve using ANCOVA model, in which the unit of the activity is pmol/min.</description>
        <time_frame>predose (0 hr) and 48 hrs post dose</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single oral dose of matching placebo to DBPR108 25 mg, 100 mg, 300 mg or 600 mg.</description>
          </group>
          <group group_id="O2">
            <title>DBPR108 25 mg</title>
            <description>Participants received a single oral dose of DBPR108 25 mg</description>
          </group>
          <group group_id="O3">
            <title>DBPR108 100 mg</title>
            <description>Participants received a single oral dose of DBPR108 100 mg</description>
          </group>
          <group group_id="O4">
            <title>DBPR108 300 mg</title>
            <description>Participants received a single oral dose of DBPR108 300 mg</description>
          </group>
          <group group_id="O5">
            <title>DBPR108 600 mg</title>
            <description>Participants received a single oral dose of DBPR108 600 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Dipeptidyl Peptidase 4 (DPP4) Activities Between 48 Hrs Post Dose and 0 hr Predose</title>
          <description>Change of plasma DPP4 activity at 48 hrs post dose from predose (0 hr). The values were computed as areas under the DPP4 activity-time curve using ANCOVA model, in which the unit of the activity is pmol/min.</description>
          <population>All enrolled participants.</population>
          <units>h*pmol/min</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-114" spread="371"/>
                    <measurement group_id="O2" value="-925" spread="464"/>
                    <measurement group_id="O3" value="-1510" spread="556"/>
                    <measurement group_id="O4" value="-2170" spread="458"/>
                    <measurement group_id="O5" value="-2350" spread="671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Day -1 (baseline) through the end of the study, up to Day 7.</time_frame>
      <desc>No text entered.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received either a single oral dose of matching placebo to DBPR108 25 mg, 100 mg, 300 mg, or 600 mg</description>
        </group>
        <group group_id="E2">
          <title>DBPR108 25 mg</title>
          <description>Participants received a single oral dose of DBPR108 25 mg</description>
        </group>
        <group group_id="E3">
          <title>DBPR108 100 mg</title>
          <description>Participants received a single oral dose of DBPR108 100 mg</description>
        </group>
        <group group_id="E4">
          <title>DBPR108 300 mg</title>
          <description>Participants received a single oral dose of DBPR108 300 mg</description>
        </group>
        <group group_id="E5">
          <title>DBPR108 600 mg</title>
          <description>Participants received a single oral dose of DBPR108 600 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Infection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament Sprain</sub_title>
                <description>Ligament Sprain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <description>Platelet Count Decreased</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <description>Haematuria</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yi-Jen Chen</name_or_title>
      <organization>Taipei Medical University - Wanfang Hospital</organization>
      <phone>886-2-2930-7930 ext 2543</phone>
      <email>yjchen@tmu.edu.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

